The Role of Nonsteroidal Anti-inflammatory Drugs in the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Abstract
Post-ERCP pancreatitis (PEP) is the most common major complication associated with ERCP. Beginning with an overview of the risk factors for the development of PEP, this review introduces the mechanism of injury in PEP and the role of pharmacological prevention. NSAIDs are increasingly found to offer prevention against the development of PEP, and their mechanism and supportive data are summarized, especially in relationship to the practice of prophylactic pancreatic duct stenting.
Image: University of Tennessee Health Science Center. Memphis, TN, USA.
Downloads
References
Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ et al. Complications of endoscopic biliary
sphincterotomy. N Engl J Med, 335 (1996), pp. 909–918
Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am, 1990; 19:793.
Freeman ML, DiSario JA, Nelson DB, Fennerty MB, Lee JG, Bjorkman DJ et al. Risk factors for post-ERCP pancreatitis: a prospective, multicenter study Gastrointest Endosc, 54 (2001), pp. 425–434
Christoforidis E, Goulimaris I, Kanellos I, Tsalis K, Demetriades C, Betsis D - Post-ERCP pancreatitis and hyperamylasemia: patient-related and operative risk factors. Endoscopy, 2002; 34(4); 286-92
Loperfido S, Angelini G, Benedetti G, Chilovi F, Costan F, De Berardinis F et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc, 48 (1998), pp. 1–10
Masci E, Toti G, Mariani A, Curioni S, Lomazzi A, Dinelli M et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol, 96 (2001), pp. 417–423
Mariani A, Giussani A, Di Leo M, Testoni S, Testoni PA. Guidewire biliary cannulation does not reduce post-ERCP pancreatitis compared with the contrast injection technique in low-risk and high-risk patients. Gastrointest Endosc. 2012 Feb;75(2):339-46.
Wang et al. Risk Factors for ERCP-Related Complications: A Prospective Multicenter Study. Am J Gastroenterol 2009; 104:31-40.
Cheng CL, Sherman S, Watkins JL et al. Risk factors for post-ERCP pancreatitis: a prospective multicenter study. Am J Gastroenterol. 2006 Jan;101(1):139-47
DeBenedet AT, Raghunathan TE, Wing JW, Wamsteker E, and Dimagno MJ. Alcohol Use and Cigarette Smoking as Risk Factors for Post–Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Clinical Gastroenterology and Hepatology, 2009, Volume 7, Issue 3, Pages 353-358.e4
Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: a comprehensive review. Gastrointest Endosc. 2006 Jun; 59 (7): 845-864
Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, Roy PK. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011;73:275–282
Sofuni A, Maguchi H, Mukai T, Kawakami H, Irisawa A, Kubota K, Okaniwa S, Kikuyama M, Kutsumi H, Hanada K, et al. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients. Clin Gastroenterol Hepatol. 2011 Oct; 9(10):851-8; quiz e110. Epub 2011 Jul 13.
Dumonceau JM, Andriulli A, Deviere J, Mariani A, Rigaux J, Baron TH, Testoni PA. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy. 2010;42:503–515
Bakman YG, Safdar K, Freeman ML. Significant clinical implications of prophylactic pancreatic stent placement in previously normal pancreatic duscts. Endoscopy. 2009 Dec; 41(12): 1095-8
Murray WR. Reducing the incidence and severity of post ERCP pancreatitis. Scand J Surg. 2005;94(2):112-6
Johnson GK, Geenen JE, Bedford RA. A comparison of nonionic versus ionic contrast media: results of a prospective, multicenter study. Midwest Pancreaticobiliary
Study Group. Gastrointest Endosc. 1995 Oct;42(4):312-6.
Sherman S, Hawes RH, Rathgaber SW et al. Post-ERCP pancreatitis: Randomized, prospective study comparing a low- and high-osmolality contrast agent. Gastrointest Endosc. 1994 Jul-Aug;40(4):422-7.
Pezzilli R, Romboli E, Campana D, Corinaldesi R. Mechanisms Involved in the Onset of Post-ERCP Pancreatitis. JOP 2002; 3(6): 162-168.
Tulassy Z, Papp J, Koranyi L, Szathmari M, Tamas G Jr. Hormonal and biochemical changes following endoscopic retrograde cholangio-pancreatography. Acta Gastroenterol Belg 1981; 44:538-44
Koike H, Steer ML, Meldolesi J. Pancreatic effects of ethionine: blockade of exocytosis and appearance of crinophagy and autophagy precede cellular necrosis. Am J Physiol 1982; 242:G297-307
Saluja AK, Donovan EA, Yamanaka K, Yamaguchi Y, Hofbauer B, Steer ML. Cerulein-induced in vitro activation of trypsinogen in rat pancreatic acini is mediated by cathepsin B. Gastroenterology Volume: 113 Issue: 1 (1997-07-01) p. 304-310
Granger J, Remick D. Acute Pancreatitis: models, markers, and mediators. Shock. 2005 Dec; 24(1): 45-51
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology. 1971 June 23; 231:232-236.
Lee SH, Soyoola E, Chanmugam P, et al. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. Journal of Biol Chem.1992 Dec 25; 267(36): 25934-25938.
Zabel-Langhenning A, Holler B, Engeland K, Mossner J. Cyclooxygenase-2 transcription is stimulated and amylase secretion is inhibited in pancreatic acinar cells after induction of acute pancreatitis. Biochem Biophys Res Commun. 1999 Nov 19;265(2):545-9.
Vollmar B, Waldner H, Schmad J, Conzen PF et al. Release of arachidonic acid metabolites during acute pancreatitis in pigs. Scand J Gastroenterol. 1989 Dec;24(10):1253-64.
Ethridge RT, Chung DH, Slogoff M, et al. Cyclooxygenase-2 gene disruption attenuates the severity of acute pancreatitis and pancreatitis-associated lung injury. Gastroenterology. 2002 Oct;123(4):1311-22.
Foitzik T, Hotz HG, Hotz B, Wittig F et al. Selective inhibition of cyclooxygenase-2 (COX-2) reduces prostaglandin E2 production and attenuates systemic disease sequelae in experimental pancreatitis. Hepatogastroenterology. 2003 Jul-Aug;50(52):1159-62.
O’Brien G, Shields CJ, Winter DC, Dillon JP et al. Cyclooxygenase-2 plays a central role in the genesis of pancreatitis and associated lung injury. Hepatobiliary Pancreat Dis Int. 2005 Feb;4(1):126-9.
Seo SW, Jung WS, Piao TG, Hong SH et al. Selective cyclooxygenase-2 inhibitor ameliorates cholecystokinin-octapeptide-induced acute pancreatitis in rats. World J Gastroenterol. 2007 Apr 28;13(16):2298-304.
Dennis EA, Cao J, Hsu YH, et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011 Oct 12;111(10):6130-85.
Uhl W, Schrag HJ, Schmitter N, Nevalainen TJ et al. Pathophysiological role of secretory type I and II phospholipase A2 in acute pancreatitis: an experimental study in rats. Gut. 1997 Mar;40(3):386-92.
Kihara Y, Yoshikawa H, Honda H, Fukumitsu K. Natural disruption of group 2 phospholipase A2 gene protects against choline-deficient ethionine-supplemented diet-induced acute pancreatitis and lung injury. Pancreas. 2005 Jul;31(1):48-53.
Buchler, Malfertheiner P, Schadlich H, Nevalainen TJ et al. Role of phospholipase A2 in human acute pancreatitis. Gastroenterology. 1989 Dec;97(6):1521-6.
Gronroos JM, Nevalainen TJ. Increased concentrations of synovial-type phospholipase A2 in serum and pulmonary and renal complications in acute pancreatitis. Digestion. 1992;52(3-4):232-6.
Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest. 1997 Aug;57(5):401-7.
Díaz-González F, Sánchez-Madrid F. Inhibition of leukocyte adhesion: an alternative mechanism of action for anti-inflammatory drugs. Immunol Today. 1998 Apr;19(4):169-72.
González-Alvaro, I., Carmona, L., Díaz-González, F., González-Amaro, R et al. Aceclofenac, a new nonsteroidal antiinflammatory drug, decreases the expression and function of some adhesion molecules on human neutrophils. J Rheum. 1996; 23(4): 723-729.
Diaz-Gonzalez, F., Gonzalez-Alvaro, I., Campanero, M.R., Mollinedo, F et al. Prevention of in vitro neutrophil-endothelial attachment through shedding of L-selectin by nonsteroidal antiinflammatory drugs. J Clin Invest. 1995; 95(4):1756-1765.
Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995 Jun 8;332(23):1553-9.
Prevention of αIIbβ3 activation by non-steroidal antiinflammatory drugs
Dominguez-Jimwnez C, Diaz-Gonzalez F, Gonzalez-Alvaro I, Cesar JM, Sanchez-Madrida F. Prevention of αII(b)β3 activation by non-steroidal antiinflammatory drugs. FEBS Letters. 12 March 1999; 446( 2–3): 318–322.
García-Vicuña R, Díaz-González F, González-Alvaro I. Prevention of cytokine-induced changes in leukocyte adhesion receptors by nonsteroidal antiinflammatory drugs from the oxicam family. Arthritis Rheum. 1997 Jan;40(1):143-53.
Gerli R, Paolucci C, Gresele P et al. Salicylates inhibit adhesion and transmigration of T lymphocytes by preventing integrin activation induced by contact with endothelial cells. Blood. 1998 Oct 1;92(7):2389-98.
Lankisch PG KH, Winckler K, et al. Indomethacin treatment of acute experimental pancreatitis in the rat. Scand J Gastroenterol 1978;13:629-33.
Ebbehøj N FJ, Svendsen LB, et al. Indomethacin treatment of acute pancreatitis. A controlled double-blind trial. Scand J Gastroenterol 1985;20:798-800.
Murray B, Carter R, Imrie C, et al. Diclofenac reduces the incidence of acute pancreatitis
after endoscopic retrograde cholangiopancreatography. Gastroenterology 2003;124:1786-91.
Sotoudehmanesh R, Khatibian M, Kolahdoozan S, et al. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol 2007;102:978-83.
Khoshbaten M, Khorram H, Madad L, et al. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol 2008;23:e11-6
Montano Loza A, Rodriguez Lomeli X, Garcia Correa JE, et al. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig 2007;99:330-6
Cheon YK, Cho KB, Watkins JL, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc 2007;66:1126-32.
Elmunzer BJ, Waljee AK, Elta GH, et al. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut 2008;57:1262-7.
Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: a meta-analysis. Hepatobiliary Pancreat Dis Int 2009;8:11-6.
Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol 2009;15:3999-4004.
Elmi F RF, Lim JK, et al. A Prospective, Multicenter, Randomized, Double Blinded Controlled Study to Determine Whether A Single Dose of Intraduodenal Indomethacin Can Decrease the Incidence and Severity of Post-ERCP Pancreatitis. Gastrointest Endosc 2010:AB232.
Otsuka T, Kawazoe S, Nakashita S, et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol 2012;47:912-7.
Bhatia V, Ahuja V, Acharya SK, et al.A randomized controlled trial of valdecoxib and glyceryl trinitrate for the prevention of post-ERCP pancreatitis. J Clin Gastoenterol. 2011 Feb;45(2):170-6
Mennecier D, Ceppa F, Sinayoko L,Acute pancreatitis after treatment by celecoxib. Gastroenterol Clin Biol. 2007 Aug-Sep;31(8-9 Pt 1):668-9.
Nind G, Selby W. Acute pancreatitis: a rare complication of celecoxib. Intern Med J. 2002 Dec;32(12):624-5.
Amaravadi RK, Jacobsen BC, Solomon DG, Fishcr MA. Acute pancreatitis associated with rofecoxib. Am J Gastroenterol. 2002 Apr;97(4):1077-8.
Carrillo-Jimenez R, Nurnberger M. Celecoxib-induced acute pancreatitis and hepatitis: a case report. Arch Intern Med. 2000 Feb 28;160(4):553-4.
Elmunzer BJ, Scheiman JM, Lehman GA, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med 2012;366:1414-22.
Baron TH, Abu Dayyeh BK, Zinsmeister AR. Rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Jul 19; 367(3):277-8; author reply 278-9.
Ding X, Chen M, Huang S, et al. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc 2012;76:1152-9.
Akbar A, Abu Dayyeh BK, Baron TH, et al. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol 2013;11:778-783.
Copyright (c) 2014 Imran Sheikh, Eric Fontenot, Nisheet Waghray, Mohammad K Ismail, Claudio Tombazzi, J Lacey Smith
This work is licensed under a Creative Commons Attribution 4.0 International License.
As a member of Publisher International Linking Association, PILA, iMedPub Group’s JOP follows the Creative Commons Attribution License and Scholars Open Access publishing policies. Journal of the Pancreas is the Council Contributor Member of Council of Science Editors (CSE) and following the CSE slogan Education, Ethics, and Evidence for Editors.